Studies evaluating neuromuscular blocking agents (NMBAs) in the management of ARDS have produced inconsistent results in terms of their effect on mortality. The purpose of this systematic review and meta-analysis was to evaluate differences in mortality comparing subjects with ARDS who received NMBA to those who received placebo or usual care.
METHODS:
We searched Ovid, MEDLINE, Embase, CINAHL, Cochrane, Scopus, and Web of Science for randomized controlled trials evaluating administration of NMBAs in subjects with ARDS.
RESULTS:
We included 6 studies (N = 1,558 subjects) from 1,814 abstracts identified by our search strategy. The use of early, continuous-infusion NMBAs reduces the risk of short-term (ie, 21–28-d) mortality (relative risk 0.71 [95% CI 0.52–0.98], P = .030, I2 = 60%) in subjects with ARDS but does not reduce the risk of long-term (ie, 90-d) mortality (relative risk 0.81 [95% CI 0.64–1.04], P = .10, I2 = 54%). NMBAs decreased the risk of barotrauma (relative risk 0.55 [95% CI 0.35–0.85], P = .008, I2 = 0%) and pneumothorax (relative risk 0.46 [95% CI 0.28–0.77], P = .003, I2 = 0%) compared to control.
CONCLUSIONS:
In subjects with ARDS, early use of NMBAs improves oxygenation, reduces the incidence of ventilator-induced lung injury, and decreases 21–28-d mortality, but it does not improve 90-d mortality. NMBAs should be considered for select patients with moderate-to-severe ARDS for short durations.
FanE, Del SorboL, GoligherEC, HodgsonCL, MunshiL, WalkeyAJ, et al. An official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine clinical practice guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med, 2017; 195(9):1253–1263.
3.
BrowerRG, MatthayMA, MorrisA, SchoenfeldD, ThompsonBT, WheelerA. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med, 2000; 342(18):1301–1308.
SlutskyAS. Neuromuscular blocking agents in ARDS. N Engl J Med, 2010; 363(12):1176–1180.
6.
GattinoniL, MariniJJ. Prone positioning and neuromuscular blocking agents are part of standard care in severe ARDS patients: we are not sure. Intensive Care Med, 2015; 41(12):2201–2203.
7.
HraiechS, ForelJM, PapazianL. The role of neuromuscular blockers in ARDS: benefits and risks. Curr Opin Crit Care, 2012; 18(5):495–502.
8.
GainnierM, RochA, ForelJM, ThirionX, ArnalJM, DonatiS, et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med, 2004; 32(1):113–119.
9.
ForelJM, RochA, MarinV, MicheletP, DemoryD, BlacheJL, et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med, 2006; 34(11):2749–2757.
10.
PapazianL, ForelJM, GacouinA, Penot-RagonC, PerrinG, LoundouA, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med, 2010; 363(12):1107–1116.
11.
LyuG, WangX, JiangW, CaiT, ZhangY. [Clinical study of early use of neuromuscular blocking agents in patients with severe sepsis and acute respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, 2014; 26(5):325–329.
12.
GuervillyC, BisbalM, ForelJM, MechatiM, LehingueS, BourenneJ, et al. Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome. Intensive Care Med, 2017; 43(3):408–418.
13.
National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, MossM, HuangDT, BrowerRG, FergusonND, GindeAA, et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med, 2019; 380(21):1997–2008.
14.
BellaniG, LaffeyJG, PhamT, FanE, BrochardL, EstebanA, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA, 2016; 315(8):788–800.
15.
DuggalA, RezoagliE, PhamT, McNicholasBA, FanE, BellaniG, et al. Patterns of use of adjunctive therapies in patients with early moderate to severe ARDS: insights from the LUNG SAFE study. Chest, 2020; 157(6):1497–1505.
16.
JørgensenL, Paludan-MüllerAS, LaursenDRT, SavovićJ, BoutronI, SterneJAC, et al. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. Syst Rev, 2016; 5:80.
17.
BalshemH, HelfandM, SchünemannHJ, OxmanAD, KunzR, BrozekJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol, 2011; 64(4):401–406.
18.
DerSimonianR, LairdN. Meta-analysis in clinical trials. Control Clin Trials, 1986; 7(3):177–188.
19.
EggerM, Davey SmithG, SchneiderM, MinderC. Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997; 315(7109):629–634.
20.
De JongheB, SharsharT, LefaucheurJP, AuthierFJ, Durand-ZaleskiI, BoussarsarM, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA, 2002; 288(22):2859–2867.
21.
AlhazzaniW, AlshahraniM, JaeschkeR, ForelJM, PapazianL, SevranskyJ, et al. Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. Crit Care, 2013; 17(2):R43.
22.
TaoW, YangLQ, GaoJ, ShaoJ. Neuromuscular blocking agents for adult patients with acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. J Trauma Acute Care Surg, 2018; 85(6):1102–1109.
23.
BlanchL, VillagraA, SalesB, MontanyaJ, LucangeloU, LujánM, et al. Asynchronies during mechanical ventilation are associated with mortality. Intensive Care Med, 2015; 41(4):633–641.
24.
AkoumianakiE, LyazidiA, ReyN, MatamisD, Perez-MartinezN, GiraudR, et al. Mechanical ventilation-induced reverse-triggered breaths: a frequently unrecognized form of neuromechanical coupling. Chest, 2013; 143(4):927–938.
25.
SlutskyAS, VillarJ. Early paralytic agents for ARDS? Yes, no, and sometimes. N Engl J Med, 2019; 380(21):2061–2063.
PriceDR, MikkelsenME, UmscheidCA, ArmstrongEJ. Neuromuscular blocking agents and neuromuscular dysfunction acquired in critical illness: a systematic review and meta-analysis. Crit Care Med, 2016; 44(11):2070–2078.
29.
SteingrubJS, LaguT, RothbergMB, NathansonBH, RaghunathanK, LindenauerPK. Treatment with neuromuscular blocking agents and the risk of in-hospital mortality among mechanically ventilated patients with severe sepsis. Critical Care Med, 2014; 42(1):90–96.
30.
MurrayMJ, DeBlockH, ErstadB, GrayA, JacobiJ, JordanC, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med, 2016; 44(11):2079–2103.
31.
GuérinC, ReignierJ, RichardJC, BeuretP, GacouinA, BoulainT, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med, 2013; 368(23):2159–2168.
